[go: up one dir, main page]

SV2009003231A - Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o implementar la libido femenina - Google Patents

Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o implementar la libido femenina

Info

Publication number
SV2009003231A
SV2009003231A SV2009003231A SV2009003231A SV2009003231A SV 2009003231 A SV2009003231 A SV 2009003231A SV 2009003231 A SV2009003231 A SV 2009003231A SV 2009003231 A SV2009003231 A SV 2009003231A SV 2009003231 A SV2009003231 A SV 2009003231A
Authority
SV
El Salvador
Prior art keywords
estradiol
combination
dienogest
maintain
implement
Prior art date
Application number
SV2009003231A
Other languages
English (en)
Inventor
Susan Zeun
Holger Zimmermann
Susanne Parke
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of SV2009003231A publication Critical patent/SV2009003231A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA INVENCIÓN SE RELACIONA CON EL USO DE VALERATO DE ESTRADIOL O 17BETA-ESTRADIOL (ESTRADIOL) EN COMBINACIÓN CON 17ALFA-CIANOMETIL-17-BETA-HIDROXIESTRA-4,9-DIEN-3-ONA (DIENOGEST) EN UN PRODUCTO COMBINADO DE MÚLTIPLES FASES O DE UNA SOLA FASE EN UNA TERAPIA ORAL PARA MANTENER Y/O INCREMENTAR LA LIBIDO FEMENINA, CUANDO FUERA APROPIADO TAMBIÉN JUNTO CON UNA CONTRACEPCIÓN ORAL. LAS UNIDADES DE DOSIS DIARIAS TOTALES DE LA COMBINACIÓN DE MÚLTIPLES FASES Y DEL PLACEBO FARMACÉUTICAMENTE ACEPTABLE O LAS UNIDADES DE DOSIS DIARIAS DE LA COMBINACIÓN DE UNA SOLA FASE Y SIN INGREDIENTE ACTIVO Y SIN PLACEBO CORRESPONDEN A 28 DÍAS
SV2009003231A 2006-10-20 2009-04-20 Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o implementar la libido femenina SV2009003231A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06022091 2006-10-20
EP07009373A EP1930010A1 (de) 2006-10-20 2007-05-10 Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Publications (1)

Publication Number Publication Date
SV2009003231A true SV2009003231A (es) 2009-11-09

Family

ID=38809728

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003231A SV2009003231A (es) 2006-10-20 2009-04-20 Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o implementar la libido femenina

Country Status (17)

Country Link
US (1) US8349820B2 (es)
EP (2) EP1930010A1 (es)
JP (1) JP2010506867A (es)
KR (1) KR20090080989A (es)
AU (1) AU2007312626A1 (es)
BR (1) BRPI0717462A2 (es)
CA (1) CA2666829C (es)
CO (1) CO6160297A2 (es)
CR (1) CR10732A (es)
EA (1) EA016631B1 (es)
GT (1) GT200900090A (es)
IL (1) IL198200A (es)
MX (1) MX2009004179A (es)
NO (1) NO20091954L (es)
NZ (1) NZ576336A (es)
SV (1) SV2009003231A (es)
WO (1) WO2008046559A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US20070088011A1 (en) * 2005-10-17 2007-04-19 Susan Zeun Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4168068A (en) 1969-07-22 1971-01-28 Unisearch Limited Improvements in or relating to oral contraceptives
US3639600A (en) * 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US3795734A (en) * 1970-04-20 1974-03-05 American Home Prod Cyclic regimen of hormone administration for contraception
US4066757A (en) * 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
DE2365103C3 (de) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
DE2431704A1 (de) 1974-07-02 1976-01-22 Asche Ag Stufenkombinationspraeparate per kontrazeption
DE2645307A1 (de) 1976-10-05 1978-04-06 Schering Ag Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) * 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3341638A1 (de) 1983-11-17 1984-05-03 Hermann Dr.rer.nat. 8000 München Heßlinger Dreiphasen-praeparat zur empfaengnisverhuetung aus ethinyloestradiol und lynestrenol
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
AU581486B2 (en) 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
CA2005933A1 (en) 1989-01-09 1990-07-09 Jesse Hipps, Sr. Photohardenable composition containing five member aromatic group with imine moiety
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (es) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4308406C1 (de) 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
DE4313926A1 (de) 1993-04-28 1994-11-03 Jenapharm Gmbh Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption
DE4339934C2 (de) 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Ovulationshemmendes Mittel zur hormonalen Kontrazeption
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
PT921804E (pt) 1996-07-26 2004-01-30 Wyeth Corp Metodo contraceptivo bifasico e conjunto ("kit") compreendendo uma combinacao de uma progestina e um estrogenio
AU3888597A (en) 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
ES2223081T3 (es) 1996-07-26 2005-02-16 Wyeth Metodo anticonceptivo oral monofasico y kit que comprende una combinacion de progestina y estrogeno.
PT917466E (pt) 1996-07-26 2004-12-31 Wyeth Corp Contraceptivo oral
US6987101B1 (en) * 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19908762A1 (de) * 1999-02-18 2000-08-31 Jenapharm Gmbh Verwendung von Dienogest in hoher Dosierung
DE10045380A1 (de) 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
US6699820B2 (en) * 2001-03-02 2004-03-02 Hartmut Ulrich Bielefeldt Method for making a superconductor with enhanced current carrying capability
IL161105A0 (en) * 2001-09-29 2004-08-31 Solvay Pharm Gmbh Estrogen/gestagen combination preparation and application thereof
EP1462106A1 (en) 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
PT1635843E (pt) 2003-06-25 2009-04-07 Bayer Schering Pharma Ag Terapia de substituição hormonal e de depressão compreendendo dienogest
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
WO2006042021A2 (en) * 2004-10-07 2006-04-20 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
TW200726473A (en) 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
DE502005006837D1 (de) 2005-10-13 2009-04-23 Bayer Schering Pharma Ag Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Also Published As

Publication number Publication date
CA2666829A1 (en) 2008-04-24
EA016631B1 (ru) 2012-06-29
WO2008046559A1 (de) 2008-04-24
MX2009004179A (es) 2009-04-30
NO20091954L (no) 2009-05-19
IL198200A0 (en) 2009-12-24
JP2010506867A (ja) 2010-03-04
BRPI0717462A2 (pt) 2013-12-24
CA2666829C (en) 2012-02-07
AU2007312626A1 (en) 2008-04-24
NZ576336A (en) 2012-03-30
EP2083827A1 (de) 2009-08-05
US20080125401A1 (en) 2008-05-29
EA200900491A1 (ru) 2009-10-30
US8349820B2 (en) 2013-01-08
KR20090080989A (ko) 2009-07-27
CR10732A (es) 2009-05-25
GT200900090A (es) 2011-11-29
CO6160297A2 (es) 2010-05-20
EP1930010A1 (de) 2008-06-11
IL198200A (en) 2012-10-31

Similar Documents

Publication Publication Date Title
SV2009003231A (es) Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o implementar la libido femenina
AR124134A2 (es) Formulación de uso tópico para un inhibidor de jak
ES2553742T3 (es) Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
NO20081038L (no) Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering
ES2693085T1 (es) Uso de estriol en bajas dosis
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
PE20090607A1 (es) Formulacion farmaceutica de dispersion liposomal en polvo seco
WO2017091767A3 (en) Drug formulations for cancer treatment
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
PE20250018A1 (es) Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
TW200603787A (en) Topical preparations containing ambroxol
MX347237B (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
AR065816A1 (es) Regimen anticonceptivo oral
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
WO2006076097A3 (en) Stable non-crystalline formulation comprising losartan
MX384760B (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
CU20090062A7 (es) Uso de valerato de estradiol o 17beta-estradiol en combinación con dienogest en una terapia oral para mantener y/o incrementar la líbido femenina
DOP2009000079A (es) Uso de valerato de estradiol en combinación con dienogest en una terapia oral para mantener y/o incrementar la líbido femenina
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar